Continuously optimistic about the innovative pharmaceutical industry
January 22, 2025
Source: drugdu
81
According to the AI News, CITIC Securities stated that policy support for innovative drugs is expected to further increase. In addition, the global sales of ADC drugs will reach 10.4 billion US dollars in 2023, and Chinese companies are accelerating their ADC layout and promotion, gradually ushering in a harvest period; The GLP-1 weight loss track has matured, and competition has shifted from single weight loss to multiple benefits. There are potential opportunities for new targets to go global; The IO multi antibody track AK112 has achieved a breakthrough, and TCE technology has moved from hematological tumors to solid tumors and self immunity. The global competitiveness of innovative drugs in China continues to strengthen, and the NewCo model has become a new choice for innovative drugs to go global. National policies encourage the development of innovative drugs, new technologies drive rapid industry growth, and new opportunities arise for going global. We continue to have a positive outlook on the innovative drug industry.
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Aohua Endoscope, Enters the Medical Robot Industry March 13, 2025
- The world’s first! One innovative medical device has obtained FDA breakthrough device certification March 13, 2025
- So far, my country has never exported fentanyl drugs to North America March 13, 2025
- Weiming Pharmaceutical plans to sign a sales contract worth 53.978 million yuan March 13, 2025
- Wholly-owned subsidiary Xiantai Pharmaceutical obtains Spanish AEMPS GMP compliance certificate March 13, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
